Stone Summit Wealth’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.69M Sell
3,190
-280
-8% -$330K 1% 31
2026
Q2
$4.16M Buy
3,470
+90
+3% +$92K 1.06% 32
2026
Q1
$3.11M Buy
3,380
+17
+0.5% +$17.2K 0.87% 35
2025
Q4
$3.61M Buy
3,363
+40
+1% +$38.2K 0.98% 33
2025
Q3
$2.54M Buy
3,323
+1,418
+74% +$1.06M 0.72% 44
2025
Q2
$1.49M Buy
1,905
+7
+0.4% +$5.44K 0.46% 58
2025
Q1
$1.57M Hold
1,898
– – 0.53% 59
2024
Q4
$1.47M Sell
1,898
-31
-2% -$25.7K 0.49% 58
2024
Q3
$1.71M Sell
1,929
-7
-0.4% -$6.29K 0.55% 56
2024
Q2
$1.75M Sell
1,936
-10
-0.5% -$8K 0.63% 53
2024
Q1
$1.51M Sell
1,946
-25
-1% -$17.8K 0.53% 60
2023
Q4
$1.15M Buy
1,971
+90
+5% +$52.5K 0.44% 70
2023
Q3
$1.01M Buy
1,881
+50
+3% +$25.8K 0.43% 70
2023
Q2
$859K Sell
1,831
-10
-0.5% -$4.19K 0.36% 74
2023
Q1
$632K Sell
1,841
-3
-0.2% -$1.01K 0.28% 81
2022
Q4
$675K Hold
1,844
– – 0.33% 79
2022
Q3
$596K Buy
1,844
+103
+6% +$32.6K 0.37% 76
2022
Q2
$565K Buy
1,741
+50
+3% +$15K 0.34% 74
2022
Q1
$495K Buy
+1,691
New +$435K 0.28% 84

Other funds holding LLY

Stone Summit Wealth's LLY Position: Q3 2026 in Review

Stone Summit Wealth reduced its Eli Lilly (LLY) stake by 8.1% in Q3 2026, selling an estimated $330K and leaving 3,190 shares worth $3.69M. The position accounts for 1% of the portfolio, ranked #31.

Stone Summit Wealth first reported a position in LLY in Q1 2022 and has held it in 19 quarters since. The position peaked at $4.16M in Q2 2026. 1,138 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Stone Summit Wealth held 3,190 shares of Eli Lilly worth $3.69M as of Q3 2026.
  • Stone Summit Wealth sold 280 Eli Lilly shares in Q3 2026, an estimated $330K.
  • Eli Lilly made up 1% of Stone Summit Wealth's portfolio in Q3 2026, its #31 holding.
  • Stone Summit Wealth first reported a position in Eli Lilly in Q1 2022 and has held it in 19 quarters since.
  • Stone Summit Wealth's Eli Lilly position peaked at $4.16M in Q2 2026.
  • 1,138 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Stone Summit Wealth's 13F filing for Q3 2026, filed 14 Oct 2026.